文献速递肺结节与肺癌呼吸道感染

经支气管纵隔冷冻活检联合EBUS-TBNA诊断纵隔疾病:多中心随机试验

Transbronchial needle aspiration combined with cryobiopsy in the diagnosis of mediastinal diseases: a multicentre, open-label, randomised trial.
PubMed 文献 · Lancet Respir Med · 2022-10-22

这项多中心开放标签随机试验纳入271例纵隔病变患者,比较EBUS-TBNA联合经支气管纵隔冷冻活检与单用EBUS-TBNA。

要点

  • 联合冷冻活检可显著提高纵隔病变总体诊断率,尤其对良性病变。
  • 联合方案未增加3-4级气道出血等操作相关并发症。
  • 联合组组织样本更适于非小细胞肺癌分子和免疫分析。

核心结论

  • 在标准EBUS-TBNA基础上加做纵隔冷冻活检可显著提高纵隔病变诊断率,且安全性良好。
  • 联合方案可作为纵隔疾病的一线诊断工具。

研究设计与样本

  • 多中心、开放标签、随机对照试验,在欧洲和亚洲三个中心开展。
  • 纳入271例年龄≥15岁、至少一个短轴≥1 cm纵隔病变需诊断性支气管镜的患者,随机1:1分为联合组(n=136)和对照组(n=135)。
  • 主要终点为操作相关并发症差异和诊断率,采用全分析集及个体内配对分析。

关键数值与推荐

  • 纵隔病变短轴≥1 cm且需诊断性支气管镜的患者可考虑联合冷冻活检。
  • 联合方案对良性纵隔病变诊断优势明显,对纵隔转移诊断率与标准针吸相当。
  • 联合方案可改善非小细胞肺癌组织样本对分子和免疫分析的适用性。

临床怎么用

  • 对怀疑良性纵隔疾病或需更多组织做分子检测者,可在EBUS-TBNA基础上加做纵隔冷冻活检。
  • 联合操作未增加严重出血风险,但仍需按规范评估气道出血风险。

局限性

  • 开放标签设计,参与者和研究者均未设盲。
  • 研究仅在欧洲和亚洲三个中心开展,外推性需进一步验证。
  • 部分亚组分析样本量较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transbronchial mediastinal cryobiopsy is a novel sampling technique for mediastinal disease. Despite the possibility of lung cancer misdiagnosis, the improved diagnostic yield of this approach for non-lung-cancer lesions compared with standard endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) highlights its diagnostic potential as a complementary technique to conventional biopsy. We aimed to evaluate the safety profile and added value of the combined use of transbronchial mediastinal cryobiopsy and standard EBUS-TBNA for the diagnosis of mediastinal diseases. METHODS: We conducted an open-label, randomised trial at three hospital sites in Europe and Asia. Eligible patients were aged 15 years or older, with at least one mediastinal lesion of 1 cm or longer in the short axis that required diagnostic bronchoscopy. Participants were randomly assigned (1:1) using a block randomisation scheme generated by a computer (block size of four participants based on a random table from an independent statistician) to the combined use of EBUS-TBNA and transbronchial mediastinal cryobiopsy (combined group) or EBUS-TBNA alone (control group). Because of the nature of the intervention, neither participants nor investigators were masked to group assignment. The coprimary outcomes were differences in procedure-related complications and diagnostic yield (defined as the proportion of participants for whom mediastinal biopsy led to a definitive diagnosis), assessed in the full analysis set, including all the patients who met the eligibility criteria and had a biopsy. A fully paired, intraindividual diagnostic analysis in participants who had both needle aspiration and mediastinal cryobiopsy was conducted, in addition to interindividual comparisons. This trial is now complete and is registered with ClinicalTrials.gov, NCT04572984. FINDINGS: Between Oct 12, 2020, and Sept 9, 2021, 297 consecutive patients were assessed for eligibility and 271 were enrolled and randomly assigned to the combined group (n=136) or the control group (n=135). The addition of cryobiopsy to standard sampling significantly increased the overall diagnostic yield for mediastinal lesions, as shown by both interindividual (126 [93%] of 136 participants in the combined group vs 109 [81%] of 135 in the control group; risk ratio [RR] 1·15 [95% CI 1·04-1·26]; p=0·0039) and intraindividual (126 [94%] of 134 vs 110 [82%] of 134; RR 1·15 [95% CI 1·05-1·25]; p=0·0026) analyses. In subgroup analyses in the intraindividual population, diagnostic yields were similar for mediastinal metastasis (68 [99%] of 69 participants in the combined group vs 68 [99%] of 69 in the control group; RR 1·00 [95% CI 0·96-1·04]; p=1·00), whereas the combined approach was more sensitive than standard needle aspiration in benign disorders (45 [94%] of 48 vs 32 [67%] of 48; RR 1·41 [95% CI 1·14-1·74]; p=0·0009). The combined approach also resulted in an improved suitability of tissue samples for molecular and immunological analyses of non-small-cell lung cancer. The incidence of adverse events related to the biopsy procedure did not differ between trial groups, as grade 3-4 airway bleeding occurred in three (2%) patients in the combined group and two (1%) in the control group (RR 0·67 [95% CI 0·11-3·96]; p=1·00). There were no severe complications causing death or disability. INTERPRETATION: The addition of mediastinal cryobiopsy to standard EBUS-TBNA resulted in a significant improvement in diagnostic yield for mediastinal lesions, with a good safety profile. These data suggest that this combined approach is a valid first-line diagnostic tool for mediastinal diseases. FUNDING: National Natural Science Foundation of China.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Fan Y, Zhang AM, Wu XL, et al. Transbronchial needle aspiration combined with cryobiopsy in the diagnosis of mediastinal diseases: a multicentre, open-label, randomised trial. Lancet Respir Med. 2022. PMID: 36279880. doi:10.1016/S2213-2600(22)00392-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。